We Audited Every Clinical Trial on Copper Peptides. There Are Three.

We sell 1% GHK-Cu serums. That makes us the least neutral party available on this question, so everything below is written to be checked rather than believed. Every number comes from a query you can re-run in about ninety seconds, and the exact queries are at the bottom.

Here is what prompted it. Several peptide sellers currently cite a 2025 meta-analysis of seven randomised controlled trials with 456 participants. We went looking for it because we wanted to cite it too. It does not exist. There is no meta-analysis of GHK-Cu. There is not even one systematic review.

So we counted the whole literature instead.

The count

PubMed, searched 24 August 2026, for GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine":

Filter Records
All records 186
Tagged humans (MeSH) 66
Publication type: clinical trial 3
Publication type: randomised controlled trial 3
Publication type: meta-analysis 0
Publication type: systematic review 0

An entire product category, sold at every price point from fifteen dollars to over a hundred and fifty, rests on three trials.

The three trials, in full

Not a sample. All of them.

1. Rabbits. 2006.

PMID 17083573, Veterinary Dermatology. "Evaluation of the effects of topical tripeptide-copper complex and zinc oxide on open-wound healing in rabbits."

Open wounds. In rabbits. This is a real study and it is not a study about your face.

2. Laser-resurfaced skin. 2006.

PMID 16847171, Archives of Facial Plastic Surgery. "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin."

Human, facial, and the closest of the three to a cosmetic context. It also studies skin recovering from ablative laser resurfacing, which is a wound. Useful, and not the same population as someone applying a serum to intact skin at night.

3. Venous stasis ulcers. 1992.

PMID 1495150, Journal of Vascular Surgery. "A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers."

Chronic leg ulcers. Wound care. Thirty-four years old.

What that adds up to

All three are wound-healing studies. The newest is from 2006. None of them tested GHK-Cu for cosmetic use on intact, healthy skin, which is what essentially every copper peptide serum on the market is sold for, ours included.

That is the finding. It is not hedged and we are not going to soften it.

What this does not mean

Being honest cuts in both directions, so here is the other side, stated as plainly as the first.

This does not mean copper peptides do nothing. Absence of trials is not evidence of absence of effect. It means the question has not been asked properly at scale, which is a different statement.

The mechanistic literature is genuinely substantial and it is where the remaining 183 papers live. GHK is an endogenous tripeptide, plasma levels decline with age, it binds copper with high affinity, and in cell and tissue models it is associated with matrix synthesis and antioxidant enzyme activity. A few we consider worth reading:

  • PMID 29986520, Int J Mol Sci 2018. Review of the gene expression data.
  • PMID 37062921, J Cosmet Dermatol 2023. Fibroblast and ex-vivo skin work on collagen IV.
  • PMID 18644225, J Biomater Sci Polym Ed 2008. Pickart's foundational tissue remodeling review.

Cell and tissue models are real evidence. They are also the weakest tier of it, and the graveyard of skincare is full of ingredients that were spectacular in a petri dish and unremarkable on a face.

What would actually settle it

A randomised, vehicle-controlled trial. Intact healthy skin. Twelve weeks minimum, because that is the collagen timeline. Instrumented endpoints rather than self-report. A disclosed concentration, so the result means something for a specific dose. A hundred-plus participants.

None of that exists. Nobody in this category has funded it, and we are not pretending we are about to either.

Why a company that sells this would publish it

The obvious question, so we will answer it directly.

Every brand in this category, us included, is selling on mechanistic plausibility rather than clinical proof. Most of them obscure that by citing papers loosely, gesturing at "40 years of research" without saying what kind, or inventing studies outright, like the meta-analysis that started this. The category has a citation-hygiene problem, and we were part of it: we found five fabricated PubMed links on our own product pages while doing this work and replaced them with real ones.

We would rather compete on being the ones who counted. If the honest state of the evidence loses us a sale to someone who wanted a guarantee, that is a sale we should lose.

Re-run this yourself

Paste any of these into PubMed. If our numbers have drifted since 24 August 2026, the newer number is the right one and we will update this page.

GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine"

(GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine") AND humans[MeSH Terms]

(GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine") AND (clinical trial[Publication Type])

(GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine") AND (meta-analysis[Publication Type])

(GHK-Cu OR "copper tripeptide-1" OR "glycyl-histidyl-lysine") AND (systematic review[Publication Type])

Use this page however you like, including against us. If you are writing about copper peptides and want the numbers, take them. A citation back is appreciated and not required.

Method note: counts are PubMed publication-type tags, which are assigned by indexers and are imperfect. A study can be a trial in substance without carrying the tag. We used the tags because they are reproducible by anyone, which matters more here than our judgement does. Last checked 24 August 2026. We re-run it quarterly.

Related

If you want the thing we sell after reading that: Dermal Recovery Serum, 1% GHK-Cu, pH 6.0, aqueous, all three numbers published. Sold on the evidence above and nothing more.

Back to blog